EGFR is overexpressed in over 90% of head and neck squamous cell carcinomas.9 Wild-type EGFR signal transduction contributes to apoptosis evasion, proliferation, angiogenesis, and metastasis.10 Cetuximab, an FDA-approved EGFR-targeted therapy for advanced OSCC,11 is associated with limitations due to resistance to it developing via alternative pathway activation.12 Additionally, mutations originating from alternative splicing of EGFR have been demonstrated to affect patient responsiveness to drug therapy. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.